A Phase 3, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled, Crossover Study to Assess the Efficacy and Safety of UX007 in the Treatment of Movement Disorders Associated With Glucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Mar 2018

At a glance

  • Drugs Triheptanoin (Primary)
  • Indications De Vivo disease
  • Focus Registrational; Therapeutic Use
  • Sponsors Ultragenyx Pharmaceutical
  • Most Recent Events

    • 06 Mar 2018 Planned End Date changed from 11 Dec 2019 to 20 Sep 2021.
    • 06 Mar 2018 Planned primary completion date changed from 11 Jul 2018 to 30 Jul 2018.
    • 20 Feb 2018 According to an Ultragenyx media release, data from this study is expected in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top